There are many reasons for pharmaceutical and biotech companies that want to conduct preclinical research in China to select Medicilon/MPI Preclinical Research Shanghai as their CRO partner - Worldwide Experience Medicilon/MPI Preclinical Research Shanghai is a joint venture formed by Shanghai Medicilon and MPI Research, two companies that, together, have conducted preclinical research for companies located on all seven continents. Knowledgeable Leadership Dr. Chun-Lin Chen, co-founder of Medicilon, Inc. as well as Shanghai Medicilon, will serve as the CEO of Medicilon/MPI Preclinical Research. Dr. Chen is a highly published thought leader in the pharmaceutical industry with extensive experience in academia, pharmaceutical, and regulatory evaluation. Ample Capacity The 50,000ft2 preclinical testing facility, located in Chuansha Economic Park in Shanghai, will be open during 2nd quarter 2008. Regulatory Familiarity Medicilon/MPI Preclinical Research Shanghai is proud to offer top quality preclinical drug discovery and development studies in an Eastern facility that meets Western regulatory standards. By 2009, the new company will be fully operational, in terms of conducting FDA/IND enabling studies, and will offer additional preclinical support services for submitting INDs and NDAs. Western Certification Standards Within the next 12 months, Medicilon/MPI Preclinical Research Shanghai will meet GLP standards and receive AAALAC accreditation. A multidisciplinary GLP advisory board originating from headquarters of MPI Research has relocated to Shanghai to drive this effort. Skilled Scientific Staff The advisory board will partner with the 70+ Shanghai Medicilon professionals who have joined the newly formed organization. Information for Current Customers of Shanghai Medicilon and MPI Research Q&A - What does it mean to our Customers/Sponsors?